HER2 gene (ERBB2) amplification and/or HER2 protein overexpression is detected in approximately 15–20% of breast cancers and is associated with more aggressive disease, progression, metastasis, and poor prognosis [13–16]. Here, ERBB2 is linked to breast carcinoma.